title: Current treatment and future prospects for peripheral T-cell lymphoma.
abstract: The management of peripheral T-cell lymphoma (PTCL) remains a big challenge. PTCL exists as a collection of subentities, which are all rare. Each subtype described has its own unique pathogenesis, etiological associations and presentation. In general, PTCL is a relatively resistant disorder that exhibits extranodal features, B symptoms and paraneoplastic phenomena. This condition is prone to relapse, with a disappointing overall survival at 5 years of approximately 30%. This review will discuss the differences in the tumor biology of PTCL subentities, their associated targeted therapies, options for first-line treatment and the role of stem cell transplantation in first-line and relapsed settings. The authors then discuss new agents being used in early phase trials in relapsed/refractory disease and discuss the urgent need for collaborative randomized controlled trials in this resistant and biologically aggressive disease group.
authors.affiliation: Department of Hematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Oxford, U.K. graham.collins@ouh.nhs.uk.
authors.forename: T A
authors.initials: TA
authors.lastname: Eyre
authors.forename: G P
authors.initials: GP
authors.lastname: Collins
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D033581:Stem Cell Transplantation
chemical_list: D056572:Histone Deacetylase Inhibitors
keywords: Bendamustine; Bortezomib; Lenalidomide; Leukemia; Non-Hodgkin's lymphoma; Pralatrexate; T-cell lymphoma